XML 57 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Net Income (Loss) Per Share - Schedule of Net Income (Loss) Per Share (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Subsidiary Sale Of Stock [Line Items]                      
Net income (loss) $ 34,000 [1] $ 53,789 [1] $ 51,338 [1] $ (102,115) [1] $ 18,078 $ 50,764 $ (5,913) $ (41,818) $ 37,012 $ 21,111 $ (142,542)
Weighted average common shares outstanding, basic 92,182,000 91,859,000 91,389,000 91,056,000 90,742,000 90,555,000 90,100,000 89,526,000 91,627,000 90,235,000 88,089,000
Effect of dilutive securities:                      
2024 Notes                 1,072,000 1,348,000 0
Weighted average common shares outstanding, diluted 97,229,000 96,074,000 94,779,000 91,056,000 95,724,000 96,798,000 90,100,000 89,526,000 95,732,000 95,386,000 88,089,000
Net income (loss) per share, basic $ 0.37 [1] $ 0.59 [1] $ 0.56 [1] $ (1.12) [1] $ 0.20 $ 0.56 $ (0.07) $ (0.47) $ 0.40 $ 0.23 $ (1.62)
Net income (loss) per share, diluted $ 0.35 [1] $ 0.56 [1] $ 0.54 [1] $ (1.12) [1] $ 0.19 $ 0.52 $ (0.07) $ (0.47) $ 0.39 $ 0.22 $ (1.62)
Stocks Options                      
Effect of dilutive securities:                      
Effect of dilutive securities                 2,559,000 3,228,000 0
Restricted Stock                      
Effect of dilutive securities:                      
Effect of dilutive securities                 449,000 564,000 0
ESPP                      
Effect of dilutive securities:                      
Effect of dilutive securities                 25,000 11,000 0
[1] In connection with the payment of the upfront fee pursuant to our collaboration and license agreement with Voyager, we recorded a charge of $113.1 million, accounted for as IPR&D, in the first quarter of 2019. In the second quarter of 2019, we entered into an amendment to the collaboration and license agreement with Voyager, pursuant to which we paid Voyager $5.0 million upfront, accounted for as IPR&D, to obtain outside the U.S. rights to the Friedreich’s ataxia program. In connection with the payment of the upfront fee pursuant to our collaboration with Xenon, we recorded a charge of $36.2 million, accounted for as IPR&D, in the fourth quarter of 2019.